Worldwide Clinical Trials Holdings

Worldwide Clinical Trials Holdings

Worldwide Clinical Trials Holdings is a global contract research organization (CRO) headquartered in the United States. The firm, led by CEO Alistair Macdonald, offers full-service clinical development support across multiple therapeutic areas including rare disease, cardiovascular and metabolic, cell and gene therapy, oncology, neuroscience, and immune-mediated inflammatory diseases. Dr. Michael Murphy serves as Chief Medical and Scientific Officer, and Lona Sheeran as Senior Vice President of Clinical Operations Early Phase. The firm provides personalized, therapeutically aligned teams for pharmaceutical and biotechnology companies, covering early-phase through late-stage clinical trials. Its services span the entire product development lifecycle, with a focus on speed, scale, and responsiveness. While Worldwide Clinical Trials maintains a global footprint (operating in countries across all regions), specific deployment figures and asset-class allocations are not publicly disclosed. Worldwide Clinical Trials positions itself as a top-rated CRO with over 30 years of experience. The firm does not disclose total professionals or number of offices publicly. In recent years, the company has emphasized its therapeutic expertise and tailored approach, though specific recent operational events or fundraising rounds are not publicly available. Alistair Macdonald was appointed CEO in early 2026 (per firm press release, 2026). The firm's structural differentiator is its therapeutic specialization combined with personalized, senior-level access — a model that contrasts with larger, more standardized CROs. The company's governance and succession framework revolve around its executive leadership team, with Macdonald as CEO, but ownership structure and ultimate beneficial owner information remain undisclosed.